Celsion Corporation (CLSN)

[BioSpecialist]

Summary ..HOT PICK

The technology is great and I believe game changing . I think you will be suitably impressed .ALWAYS DO YOUR OWN DD !!!!

Thermodox Phase III results is coming very soon .Thermodox has BLOCKBUSTER POTENTIAL (1-1,5 Billion Dollar Market Potential )

The current Market cap of 43 Million$ is too ridiculous for a BIG BLOCKBUSTER .


Celsion (CLSN)

Market Cap : 43 Mil$
Cash : 5,68 Mil$ (+Celsion Corporation Secures $15 Million)
Price : 3,50 $

Shares Out : 12,27 M


Insider Activity
http://www.secform4.com/insider-trading/749647.htm


CEO LETTER ...
http://www.celsion.com/letter.cfm


From R&R Presentation:: WATCH

THERMODOX TIMELINE
http://www.wsw.com/webcast/rrshq18/clsn/2__Slide5.JPG

MARKET POTENTIAL
http://www.wsw.com/webcast/rrshq18/clsn/2__Slide7.JPG

Commercialization Plans
http://www.wsw.com/webcast/rrshq18/clsn/2__Slide8.JPG

THERMODOX
http://www.wsw.com/webcast/rrshq18/clsn/2__Slide12.JPG

UPCOMING MILESTONES
http://www.wsw.com/webcast/rrshq18/clsn/2__Slide22.JPG


Data Monitoring Committee Unanimously Recommends Continuation of Celsion's Phase III ThermoDox(R) HEAT Study to Treat Primary Liver Cancer
http://www.celsion.com/releasedetail.cfm?ReleaseID=512752


Celsion Receives Fast Track Designation for ThermoDox(R) Development Program to Treat Primary Liver Cancer
http://www.celsion.com/releasedetail.cfm?ReleaseID=501947


Presentation Juni 2010
http://www.celsion.com/common/download/download.cfm?companyid=CLN&fileid=381216&filekey=91f619e7-1d31-4b06-9165-6b2001e1b2f2&filename=Needham%20Presentation%20FINAL%2006-09-2010.pdf


"We continue to make substantial progress recruiting patients into our Phase III HEAT trial for ThermoDox(R). We continue to track well against our goal to complete enrollment by the end of this year," said Michael Tardugno, President and CEO of Celsion. "We have exceeded our goal of opening enrollment at 70 clinical trial sites with 74 enrolling world-wide. The Phase I/II DIGNITY trial of ThermoDox(R) in patients with recurrent chest wall breast cancer (RCW) also continues to advance. We are currently enrolling patients in the 50mg/m2 dosing cohort, which will be used to determine our therapeutic dose."